Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 260 participants.
Also called NCT02948998
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 260 participants
- Sponsor
- Registry
-
NCT02948998
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02948998. Randomized; no masking; primary purpose treatment. Start 2018-05-14 (anticipated); primary completion 2019-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy
- Condition
- Hypertrophic Cardiomyopathy
- Condition
- Fibrosis
- Intervention (Drug)
- Spironolactone
- Lead sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Collaborator
- Ruijin Hospital
- Collaborator
- RenJi Hospital
- Collaborator
- Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Record details
- Record id
cardio:ct-nct02948998- Content hash
0ecf6bfbbccf9b7fc9feb45407dd891fb23cc68a1ba01f9dc764b5c597095866